TMPRSS2 and COVID-19: The COVID-19 pandemic requires special attention on patients affected by GI tumors—malignancies more common in the elderly—who already have higher ACE-2 and TMPRSS2 expression and are more likely to be affected by  other comorbidities that make them more susceptible to severe forms of COVID-19 [62].